Market news
Ligand Pharmaceuticals recently entered a US$47 million financing agreement with AvenCell Therapeutics, including up to US$6 million in Series C funding and as much as US$41 million tied to clinical milestones for AvenCell’s CAR-T therapy programs. The deal deepens Ligand’s royalty-focused model by adding potential royalty streams on AvenCell’s current and future pipeline, further broadening its portfolio of over 200 partnered assets following the XOMA Royalty acquisition. We’ll now examine...
On latest list of new buys by top funds, Ligand targets buy point.
Detailed price information for Warby Parker Inc Cl A (WRBY-N) from The Globe and Mail including charting and trades.
Detailed price information for Boston Scientific Corp (BSX-N) from The Globe and Mail including charting and trades.
This is the newest page. Registered accounts read further back.